| Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ... Cell 170 (6), 1109-1119. e10, 2017 | 1251 | 2017 |
| Sotorasib for Lung Cancers with KRAS p.G12C Mutation F Skoulidis, BT Li, GK Dy, TJ Price, GS Falchook, J Wolf, A Italiano, ... New England Journal of Medicine 384 (25), 2371-2381, 2021 | 1074 | 2021 |
| Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma I Puzanov, MM Milhem, D Minor, O Hamid, A Li, L Chen, M Chastain, ... Journal of Clinical Oncology 34 (22), 2619, 2016 | 541 | 2016 |
| Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de … T Iveson, RC Donehower, I Davidenko, S Tjulandin, A Deptala, ... The lancet oncology 15 (9), 1007-1018, 2014 | 309 | 2014 |
| Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor–neutralizing monoclonal antibody, in a first-in-human study of patients with … MS Gordon, CJ Sweeney, DS Mendelson, SG Eckhardt, A Anderson, ... Clinical Cancer Research 16 (2), 699-710, 2010 | 192 | 2010 |
| A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma PY Wen, D Schiff, TF Cloughesy, JJ Raizer, J Laterra, M Smitt, M Wolf, ... Neuro-oncology 13 (4), 437-446, 2011 | 187 | 2011 |
| Structural principles that govern the peptide-binding motifs of class I MHC molecules C Zhang, A Anderson, C DeLisi Journal of molecular biology 281 (5), 929-947, 1998 | 158 | 1998 |
| Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ... Cell 174 (4), 1031-1032, 2018 | 142 | 2018 |
| A genomic analysis of the archaeal system Ignicoccus hospitalis-Nanoarchaeum equitans M Podar, I Anderson, KS Makarova, JG Elkins, N Ivanova, MA Wall, ... Genome biology 9, 1-18, 2008 | 134 | 2008 |
| Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. GV Long, R Dummer, A Ribas, I Puzanov, A VanderWalde, ... Journal of Clinical Oncology 34 (15_suppl), 9568-9568, 2016 | 125 | 2016 |
| Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in … KS Oliner, R Tang, A Anderson, Y Lan, T Iveson, RC Donehower, Y Jiang, ... Journal of Clinical Oncology 30 (15_suppl), 4005-4005, 2012 | 107 | 2012 |
| Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected … I Puzanov, MM Milhem, RHI Andtbacka, DR Minor, O Hamid, A Li, ... Journal of clinical oncology 32 (15_suppl), 9029-9029, 2014 | 97 | 2014 |
| VRDD: applying virtual reality visualization to protein docking and design A Anderson, Z Weng Journal of Molecular Graphics and Modelling 17 (3-4), 180-186, 1999 | 82 | 1999 |
| A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors PJ Rosen, CJ Sweeney, DJ Park, DM Beaupre, H Deng, IM Leitch, ... Clinical Cancer Research 16 (9), 2677-2687, 2010 | 80 | 2010 |
| A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma P Schöffski, JA Garcia, WM Stadler, T Gil, E Jonasch, ST Tagawa, M Smitt, ... BJU international 108 (5), 679-686, 2011 | 77 | 2011 |
| Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial R Dummer, DE Gyorki, J Hyngstrom, AC Berger, R Conry, L Demidov, ... Nature medicine 27 (10), 1789-1796, 2021 | 75 | 2021 |
| Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia HP Erba, PS Becker, PJ Shami, MR Grunwald, DL Flesher, M Zhu, ... Blood Advances 3 (13), 1939-1949, 2019 | 75 | 2019 |
| Preliminary results from a phase 1 first-in-human study of AMG 673, a novel half-life extended (HLE) anti-CD33/CD3 BiTE®(bispecific T-cell engager) in patients with relapsed … M Subklewe, A Stein, RB Walter, R Bhatia, AH Wei, D Ritchie, V Bücklein, ... Blood 134, 833, 2019 | 69 | 2019 |
| Pharmacology of AMG 181, a human anti‐α4β7 antibody that specifically alters trafficking of gut‐homing T cells WJ Pan, H Hsu, WA Rees, SP Lear, F Lee, IN Foltz, P Rathanaswami, ... British Journal of Pharmacology 169 (1), 51-68, 2013 | 42 | 2013 |
| Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non–small-cell lung cancer: 2-year analysis of CodeBreaK 100 GK Dy, R Govindan, V Velcheti, GS Falchook, A Italiano, J Wolf, ... Journal of Clinical Oncology 41 (18), 3311, 2023 | 41 | 2023 |
